Big Pharma’s Continued Failure to Develop an Effective Alzheimer’s Drug: Are
Alzheimer’s Vaccines Next?
-by Paul Fassa
Health Impact News
Coconut oil and the high-fact ketogenic diet have proven effective and safe at treating dementia, Parkinson’s
disease, and Alzheimer’s. Meanwhile, the pharmaceutical industry’s continued effort at finding drugs to ameliorate Alzheimer’s and Parkinson’s have been a complete failure.
There’s too much potential profit in the baby-boomer-turning-seniors market for them to stop; Big Pharma’s boom
with cholesterol-lowering statin drugs proved that. There is still way too many who have put their faith in modern mainstream medicine, especially among baby boomers.
The next blockbuster drug revenue with Alzheimer’s and Parkinson’s may be with a new Alzheimer vaccine, since
vaccines introduced into the market do not need to be effective, and drug companies cannot be sued for any damages resulting from vaccines.
Big Pharma Targets Vulnerable Seniors’ Market
The patent for Pfizer’s cholesterol-lowering statin drug Lipitor, the biggest selling single pharmaceutical ever,
expired a few of years ago. Of course, there are still others with patents intact and generic versions popping into the market, even with ever increasing risk factors that widen the net for this
market. The market for statin or other cholesterol lowering drugs may be getting crowded.
So the venture capital from both outside and within the pharmaceutical industry shifted to creating drugs for
Alzheimer’s and Parkinson’s. Of course, with Lipitors’ sales revenue declining after its patent expired, Pfizer saw Alzheimer’s as the new older generation’s market for drugs, especially since
mainstream medicine has announced there is no cure, only progressive worsening from Alzheimer’s.
As long as pharmaceutical drugs don’t cure or kill, maintenance is profitable. Side effects, on the other hand,
create even more sales for other drugs.
Pharmaceutical Companies Folding Their Cards at Alzheimer’s
Just recently, (January 2018), Pfizer ended its research on Alzheimer’s and Parkinson’s disease drug formulations
and cut that research out of its joint venture budget with Johnson & Johnson. Both are among the world’s largest pharmaceutical companies, and their combined effort is massive, expensive, and yet
By halting Alzheimer’s and Parkinson’s research in its neuroscience discovery and development programs in
Connecticut and Massachusetts, 300 positions and jobs in those states will be eliminated, according to the Reuters January 2018 press
Some mainstream media reactions to the announcement accused Pfizer of cutting back to profit more from Trump’s recent tax cuts that are proving beneficial to
large drug companies. Merck made a
similar move in February of 2017. Some accused Merck of doing more financial engineering than pharmaceutical engineering.
Just before those two companies dropped out of the Alzheimer’s blockbuster search, Eli Lilly dropped its research along the same line in November of 2016. So of
course there was “financial engineering” involved.
Alzheimer’s victims are now at over 5 million sufferers, in America alone. The Alzheimer’s pharmaceutical market
is big and is getting bigger. By 2050 the number of Alzheimer’s victims may reach 16 million, according to the Alzheimer’s Association.
It should be noted that all of these mammoth drug companies were forced to quit, because at various stages during
their human trials, they discovered their drug of choice simply wasn’t working even among mild to moderate Alzheimer’s patients. Side
effects weren’t mentioned, but they had to be there as well.
Their drugs were not even working enough to send in only the two positive study result reports required by the FDA
for final approval while sitting on the negative reports, (an agreed upon legal arrangement that comes with $2 million plus prescription drug user fee). (PDUF)
This arrangement was made to support fast track approval, which winds up leaving medical consumers as future
guinea pigs for collateral damage from side effects.
Is a Switch to Developing Alzheimer’s Vaccines on the Horizon to Avoid
Legal Liability for a Failed Product?
Most of the failed human trials for new Alzheimer’s drugs were on people with early stages of dementia, not on
progressed late stage Alzheimer’s disease.
Some researchers and mainstream medical journalists were beginning to express doubts about the alkaloid cascade hypothesis (ACH) that all their research of slicing and dicing biochemical compounds was based on.
If that folds, there are more research jobs lost and less funding for academic institutions.
These concerns motivated efforts to double-down with the ACH and tau plaque theories and get more creative and complicated than ever. One example was expressed by a Japanese microbiologist, Yoh Matsumoto, who is
an inventor of DNA vaccines.
His paper was published in the journal Dove in 2015. Matsumoto offers a solution to the dilemma
of failing drug tests for Alzheimer’s. This is what he said in the paper’s conclusion. The emphasized phrase was added:
combined active immunization approach targeting both Aβ [amyolid beta] and tau should first be evaluated to find effective immunotherapy against AD [Alzheimer’s disease]. (Source)
This seems to be an attempt at laying the groundwork for researching Alzheimer’s vaccines. Indeed, preliminary
trials have begun for just that, according to a 2017 Alzheimer’s News Today report on Axon’s early development of a tau vaccine.
Keep in mind that patients and consumers are prohibited from seeking tort remuneration for personal injuries from
vaccines. The establishment of the vaccine court restricted and limited vaccine damage payouts to serious adverse events from vaccines.
The funds awarded come mostly from surcharges or taxes on vaccine sales that are held in a trust fund and
distributed through the National Vaccine Injury Compensation Program (NVICP). But only a handful survive the hoops to get compensated by the vaccine court; few even know about it. (Source)
Vaccines are not a financial liability to drug companies from lawsuits regardless of the damage they cause. (All
of their other drugs are a liability.) Many class action lawsuits are settled to avoid full disclosure or protracted court proceedings that attract media attention.
A settlement is usually made outside the court with a gag order on the claimant that is binding with the legal
enforcement of the defendant’s reclaiming the funds awarded if the gag order is broken. The defendant (drug company) is also able to claim no guilt with a settlement.
Big Pharma’s Statins Have Caused More Harm than Help But are Still
Most of those on cholesterol-lowering statins were put on them according to risk guidelines, not because they
initially had cardiac issues. And as mentioned earlier, those risk factors have been constantly rigged to expand statin sales.
Over one in five Americans between the ages of 40 and 75 already take a statin to lower cholesterol, the American
study from 2017 estimated. Following either of the guidelines consistently would add millions to that list, and the ACC/AHA [American College of Cardiology/American Heart Association] recommendation
in particular would more than double it.(Source)
Meanwhile, many statin users who were healthy before being prescribed statins began their descent into
debilitating muscle weakness and lowered immunity from side effects. Other side effects included heart disease, which was supposed to be prevented, due to statin drugs causing lower CoQ10
production in addition to lowering cholesterol.
Lowering cholesterol probably also ushered earlier onset dementia among many users because our brains and nervous
system need cholesterol to remain intact and healthy. Perhaps all that statin use by older folks has contributed to the Alzheimer’s and Parkinson’s epidemics by creating neurological damage due to
insufficient cholesterol. See:
That’s why everyone should simply get off statin drugs. Several tests allude to statin drugs’ failures at
preventing heart disease. In other words, statins inherently carry an overwhelming bundle of risks with virtually no benefit. Several studies also
demonstrate people with high cholesterol live longer and healthier lives. (Source)
Real Solution to Alzheimer’s is Just Too Easy, Pharma Fights to Keep it Hidden
Pharmaceutical researchers are chasing symptoms and they are unaware of the cause of Alzheimer’s. Just because the
brains of Alzheimer’s cadavers contain tau plaques and beta amyloid tangles doesn’t mean that’s what causes Alzheimer’s. These are symptoms after the fact of causation, and as some like to say,
“association is not causation.”
Now some M.D.s not inhibited by medical dogma are realizing all forms of dementia stem from what they are calling
diabetes 3. It’s very similar to diabetes 2, in that cells become insulin resistant despite an abundance of insulin, preventing adequate glucose fueling. But this syndrome is isolated to the brain,
thus the tag diabetes 3.
What is being discovered is that the opposite of statin drugs is the solution for diabetes 3 – a ketogenic diet, high in saturated fats with an emphasis on coconut oil. Even high doses of coconut oil with a regular healthy diet, has demonstrated
efficacy against Alzheimer’s disease with reports of miraculous reversals without side effects, even with late stage Alzheimer’s. (Source)
Coconut oil and the ketogenic diet creates ketones, especially as the liver metabolizes the coconut oil medium
chain triglycerides (MCT). Ketones replace glucose (sugar) as the brain cells’ fuel for metabolism to create better functioning for diabetes 3 Alzheimer’s patients, ameliorating their symptoms more
than any pharmaceutical drug can hope to accomplish. (Source)
The whole dietary and medical system, so heavily publicized and funded, is totally upside down with its approach
to dementia, neurological disease, and Alzheimer’s. Ketogenic dieting and coconut oil are the simple solutions that mainstream medicine avoid.
Seniors and the rest of us need cholesterol for several healthy functions. Big Pharma, and mainstream media don’t
want you to know this.
Health Impact News has plenty of information on the importance of cholesterol.